Press Releases

Date	Title
10/2/13	Sarepta Therapeutics Introduces Online Resource Center on Exon Skipping for the Duchenne Muscular Dystrophy Community
9/26/13	Sarepta Therapeutics Announces Eteplirsen Demonstrates Continued Stability on Walking Test Through 96 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy
8/26/13	Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
8/8/13	Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study Results in the Annals of Neurology
8/8/13	Sarepta Therapeutics Announces Second Quarter 2013 Financial Results and Recent Corporate Developments
7/30/13	Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
7/25/13	Sarepta Therapeutics to Announce Second Quarter 2013 Financial Results and Corporate Update on August 8, 2013
7/24/13	Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy in First Half of 2014
7/23/13	Sarepta Therapeutics to Host Conference Call to Discuss Regulatory Update for Eteplirsen on Wednesday, July 24, 2013
7/3/13	Sarepta Therapeutics Announces At-the-Market Equity Offering Facility

IR Menu